AIMS: To study long-term, whole population 'real-world' clinical outcomes of ranibizumab therapy in treatment-na  ve eyes for neovascular age-related @entity1020 . METHODS: Data collected prospectively from a single centre serving a defined population using an electronic medical record included: demographics, Early Treatment @entity6 Study visual acuity (ETDRS @entity22066 ) at all visits, injection dates, central 1   mm retinal thickness, and @entity260 . RESULTS: 1483 eyes from 1278 @entity1 were included in this study. The median age at the time of the @entity1 's first injection was 82.5   years, 64.9% of @entity1 were female, and another ocular pathology was present in 7.3% eyes. The baseline @entity22066 was 23-39, 40-54, 55-70 and >70 ETDRS letters for 17.3%, 23.1%, 42.7% and 16.9% of eyes, respectively. The median @entity22066 in all baseline @entity22066 groups improved after the loading phase but declined back to the baseline level by 2-5   years. The rate of @entity3225 following intravitreal injection was 1 in 2124 injections. CONCLUSIONS: These long-term real-world data demonstrate that in general @entity22066 increases during the loading phase but returns to near baseline levels after 2-5   years of treatment for each baseline @entity22066 category. @entity1 should be identified and treated as early as possible, since presenting @entity22066 predicts the @entity22066 maintained after 5   years of treatment. National Institute of Health and Care Excellence guidance advising treatment only for eyes with vision below 70 letters does not promote best long-term @entity22066 outcomes for @entity1 .

Long-term outcomes of intravitreal ranibizumab for neovascular age-related XXXX in a well defined region of the UK.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetic Retinopathy'] @entity260 :: ('MESH:D011183', 'Disease') :: ['operative and postoperative complications'] @entity22066 :: ('MESH:C563443', 'Disease') :: ['VA'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['macular degeneration'] @entity3225 :: ('MESH:D009877', 'Disease') :: ['endophthalmitis']
@entity1020 :: (MESH:D008268,Disease) :: ['macular degeneration']
